Palo Alto Networks (NasdaqGS:PANW) Q2 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAdam Borg - Managing DirectorAdam Tindle - Managing DirectorBrad Zelnick - Managing DirectorDipak Golechha - CFOGabriela Borges - Managing Director and Head of US Software Equity ResearchGregg Moskowitz - Managing DirectorHamza Fodderwala - SVP of Investor Relations and Strategic FinanceJohn DiFucci - Senior Managing DirectorJosh Tilton - Managing DirectorLee Klarich - Chief Product and Technology Offi ...

RB Global (NYSE:RBA) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsEric Guerin - CFOGary Prestopino - Managing DirectorJim Kessler - CEOJohn Gibson - Director of Equity ResearchMaxim Sytchev - Managing DirectorSabahat Khan - Managing Director of Global ResearchSameer Rathod - VP of Investor Relations and Market IntelligenceConference Call ParticipantsJohn Healy - Senior Research AnalystKrista Friesen - Equity Research AnalystMichael Feniger - Equity Research AnalystSteven Hansen - ...

Cineverse (NasdaqCM:CNVS) Q3 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsChris McGurk - Chairman and CEOErick Opeka - President and Chief Strategy OfficerGary Loffredo - Chief Legal Officer and Senior AdvisorMark Lindsey - CFOTony Huidor - President of Technology and Chief Product OfficerConference Call ParticipantsBrian Kinstlinger - Equity Research AnalystDan Kurnos - Equity Research AnalystLaura Martin - Equity Research AnalystOperatorGood day, everyone, and thank you for joining ...

Beta Bionics (NasdaqGM:BBNX) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsJeffrey Cohen - Managing Director and Director of Equity ResearchJon Block - Managing DirectorMatthew Blackman - Managing DirectorSean Saint - CEOStephen Feider - CFOConference Call ParticipantsDanielle Antalfy - Senior AnalystFrank Takkinen - Senior Research AnalystJeff Johnson - Managing Director and Senior Research AnalystMatthew O'Brien - Managing Director and Seni ...

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

TechPrecision (NasdaqCM:TPCS) Q3 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAlex Shen - CEOBrett Maas - Managing DirectorPhil Podgorski - CFORoss Taylor - Partner and Portfolio ManagerConference Call ParticipantsNone - AnalystOperatorGreetings, and welcome to the TechPrecision Corp Fiscal 2026 third quarter financial results. At this time, all participants are placed on a listen-only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce your hos ...

Financial Data and Key Metrics Changes - Fourth quarter 2025 revenue was $75.1 million, a decrease of 36.9% year-over-year, primarily due to a decrease in the number of active earning coaches [25] - Loss per share for the fourth quarter was $1.65, impacted by a $12.1 million non-cash valuation allowance against deferred tax assets, which represented $1.10 of the loss per share [24][31] - Revenue per active earning coach reached $4,664, a year-over-year increase of 6.2%, marking the first year-over-year growth since Q2 2022 [25][26] - Gross profit for Q4 2025 decreased 40.9% year-over-year to $52.1 million, with a gross profit margin of 69.4%, down 470 basis points [26] Business Line Data and Key Metrics Changes - The company ended the quarter with approximately 16,100 active earning coaches, a decrease of 40.6% from the fourth quarter of 2024 [25] - Coach productivity turned positive year-over-year for the first time since mid-2022, increasing by 6% in Q4 [12] Market Data and Key Metrics Changes - The rapid adoption of GLP-1 medications continues to impact the traditional weight loss category, contributing to the decline in active earning coaches [25] - A national survey indicated that nearly 94% of American adults express concern about at least one aspect of metabolic health, highlighting a large underserved market [9] Company Strategy and Development Direction - The company is transitioning to a metabolic health focus, emphasizing a scientific approach called Metabolic Synchronization to address metabolic dysfunction rather than just weight loss [6][8] - A new product line is being developed to support metabolic health, aiming to reduce visceral fat and improve body composition [10] - The company is committed to disciplined execution to regain profitability while maintaining financial flexibility for growth investments [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the direction of the company and the strength of the leadership team, indicating that foundational elements for future growth are now in place [11] - Early indicators of improved coach productivity and engagement are seen as signs of potential revenue growth in the future [12][20] - The company expects to see continued coach productivity growth in Q1 2026, with annual revenue guidance set between $270 million and $300 million [33] Other Important Information - The company executed a restructuring across all business functions, targeting future savings of over $30 million [28] - The balance sheet remains strong, with $167.3 million in cash and no debt as of December 31, 2025 [32] Q&A Session Summary Question: Can you provide details on coach productivity and the consumer demographics associated with them? - Management noted that the improvement in coach productivity reflects a new focus on metabolic health, attracting a different type of customer seeking health benefits beyond weight loss [36][38] Question: How do you see revenue trends progressing through 2026? - Management indicated that while they are not providing quarterly guidance, they expect stabilization and gradual improvement in revenue throughout the year, with a focus on the transition to metabolic health [41][43] Question: What insights can you share about the new product lineup and its alignment with consumer needs? - Management highlighted that there is a growing inflow of clients transitioning off GLP-1 drugs, which the company is well-positioned to attract with its new offerings [44][46]

Cineverse (NasdaqCM:CNVS) Q3 2026 Earnings call February 17, 2026 04:30 PM ET Speaker7Good day, everyone, and thank you for joining us, and welcome to the Cineverse Corporation Fiscal 2026 third quarter earnings call. My name is Luca, and I will be your operator today. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed in to today's call, please press star nine to raise your hand and star six to unmute. ...

Palo Alto Networks (NasdaqGS:PANW) Q2 2026 Earnings call February 17, 2026 04:30 PM ET Speaker5Good day, everyone, and welcome to Palo Alto Networks' fiscal second quarter 2026 earnings conference call. I am Hamza Fodderwala, Senior Vice President of Investor Relations and Strategic Finance. Please note that this call is being recorded today, Tuesday, February 17, 2026, at 1:30 P.M. Pacific Time. With me on today's call to discuss our fiscal second quarter results are Nikesh Arora, our Chairman and Chief Ex ...

Glaukos (NYSE:GKOS) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker11Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Glaukos's fourth quarter and full year 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, si ...